CACI (NYSE: CACI) Form 144 details planned sale of 3,000 shares

Rhea-AI Filing Summary

CACI has a security holder filing a notice of intent to sell 3,000 shares of common stock through broker Merrill at an aggregate market value of 1755225.46, with the sale expected on 12/10/2025 on the NYSE. Shares outstanding were 22,079,710, providing context for the size of the planned sale.

The shares planned for sale were originally acquired from CACI as stock compensation in multiple grants between 2015 and 2018, with individual awards ranging from 268 to 351 shares that together total 3,000 shares. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about CACI’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merril 11333 McCormick Road Hunt Valley MD 21031	3000	1755225.46	22079710	12/10/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/17/2015	Stock Compensation	CACI			345	08/17/2015	Stock Compensation
Common	11/15/2015	Stock Compensation	CACI			351	11/15/2015	Stock Compensation
Common	02/17/2016	Stock Compensation	CACI			307	02/17/2016	Stock Compensation
Common	05/17/2016	Stock Compensation	CACI			308	05/17/2016	Stock Compensation
Common	08/15/2016	Stock Compensation	CACI			307	08/15/2016	Stock Compensation
Common	11/13/2016	Stock Compensation	CACI			308	11/13/2016	Stock Compensation
Common	02/14/2018	Stock Compensation	CACI			268	02/14/2018	Stock Compensation
Common	05/15/2018	Stock Compensation	CACI			269	05/15/2018	Stock Compensation
Common	08/13/2018	Stock Compensation	CACI			268	08/13/2018	Stock Compensation
Common	11/09/2018	Stock Compensation	CACI			269	11/09/2018	Stock Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for CACI disclose?

The filing discloses that a CACI security holder intends to sell 3,000 shares of CACI common stock on the NYSE, using Merrill as broker, with an aggregate market value of 1755225.46.

How many CACI shares are planned to be sold under this Form 144?

The notice covers an intended sale of 3,000 shares of CACI common stock, as listed in the securities information table.

When is the CACI share sale under Form 144 expected to occur?

The approximate date of sale for the 3,000 CACI common shares is listed as 12/10/2025.

On which exchange will the CACI shares in this Form 144 be sold?

The intended sale of 3,000 CACI common shares is identified for trading on the NYSE, according to the securities information table.

How were the CACI shares in this Form 144 originally acquired?

The 3,000 shares planned for sale were acquired from CACI as stock compensation in multiple transactions between 2015 and 2018, each recorded with its own grant and payment date.

How many CACI shares are outstanding compared with this Form 144 sale?

The table shows that 22,079,710 CACI common shares were outstanding, providing a baseline compared with the planned sale of 3,000 shares.

What representation does the seller make in the CACI Form 144 notice?

By signing the notice, the seller represents that they do not know any material adverse information about CACI’s current or prospective operations that has not been publicly disclosed.